Navigation Links
A New Milestone in Stem Cell Research

In the first trial of its kind in the world, 60 patients who have recently suffered a major heart attack will be injected with selected stem cells from their own bone marrow during routine coronary bypass surgery.

The Bristol trial will test whether the stem cells will repair heart muscle cells damaged by the heart attack, by preventing late scar formation and hence impaired heart contraction.

Professor Jeremy Pearson, Associate Medical Director of the BHF, said: We hope that this exciting Bristol project will provide information taking us a step nearer to the day when stem cells can be used routinely to help repair damaged hearts.

In a heart attack, part of the heart muscle loses its blood supply (usually due to furring up of the arteries with fatty material) and cells in that part of the heart die, leaving a scar. This reduces the ability of the heart to pump blood around the body.

While the blood supply to the heart can be improved with coronary bypass surgery or angioplasty, thereby reducing the risk of further heart attacks, these techniques do not restore the viability and function of the area already damaged. In 3-6 months after surgery, 20 per cent of patients develop a thinning of the walls of the heart, which in its most extreme form, can lead to congestive heart failure.

Dr Raimondo Ascione, Consultant Cardiac Surgeon, said: I am very grateful to the British Heart Foundation for funding this important trial; the first of its kind worldwide. We have elected to use a very promising stem cell type selected from the patients own bone marrow. This approach ensures no risk of rejection or infection. It also gets around the ethical issues that would result from use of stem cells from embryonic or foetal tissue.

Current treatments aim to keep the patient alive with a heart that is working less efficiently than before the heart attack. Cardiac stem cell therapy aims to repair the damaged h eart as it has the potential to replace the damaged tissue.

In this trial (known as TransACT), all patients will have bone marrow harvested before their heart operation. Then either stem cells from their own bone marrow or a placebo will be injected into the patients damaged hearts during routine coronary bypass surgery. The feasibility and safety of this technique has already been demonstrated.

As a result of the chosen double blind placebo-controlled design, neither the patients nor the surgeon knows whether the patient is going to be injected with stem cells or placebo. This ensures that results are not biased in any way, and is the most powerful way to prove whether or not the new treatment is effective.


Related medicine news :

1. Cancer Research: Yet Another Milestone
2. Year 2010 Envisioned to be Milestone Year for Malaria Vaccine
3. Eurand and GSK Reach Development Milestone
4. Kidney Stones - Interesting New Research implicates bacteria as its cause
5. Researchers urge caution in using ear tube surgery
6. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
7. Researchers Scale to assess the Severity of Epilepsy in Kids
8. Research of Ritalin
9. Researchers trick Alzheimers Enzyme
10. Researchers find new HIV hiding place
11. A Compilation of recent Diabetes Research articles
Post Your Comments:

(Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, ... Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will take ... and will unite customers, partners, WennSoft team members and sponsors to facilitate the ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... County, Illinois with more than 59,000 emergency department visits per year, today announced ... from T-System, to help improve clinical, operational and financial outcomes. , ...
(Date:10/13/2015)... ... 2015 , ... California Southern University has named Dr. Judith ... Doctor of Nursing Practice from the renowned Johns Hopkins University—comes to CalSouthern with ... McLeod’s long and successful nursing practice included a variety of patient care, education ...
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... According ... Derrick Rose suffered an orbital fracture when a teammate accidentally elbowed him in the ... 2015. Rose's recent eye injury is just one of a series of setbacks, including ...
(Date:10/13/2015)... ... ... With Fall weather approaching and holiday travel season upon us, is giving away ... to win! , How to Enter:, 1. Like on Facebook , 2. ... us on Instagram @thebeautyplace , 4. Share Facebook Contest Image With Friends , ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... Research and Markets ( ) has announced the ... Yeast, Mold, Others), Flavors (Herbs & Spices, Citrus, Berries, ... - Forecasts to 2020" report to their offering. ... --> The global market for kombucha has grown ... value, the market is projected to reach USD 1.8 ...
(Date:10/13/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... serving the pharmaceutical, biotechnology, and medical device industries, ... version of OncoWuXi, the first App in the ... and data on the go.  The OncoWuXi App ... to identify relevant tumor models for use in ...
(Date:10/13/2015)... , Oct. 13, 2015  The ... Harvard University today announced the launch of ... Ultivue will introduce imaging reagents providing ... to those of expensive specialized instruments. The ... Harvard,s Office of Technology Development (OTD) ...
Breaking Medicine Technology: